Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

NCT02169284 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Bladder Carcinoma
Recurrent Bladder Carcinoma

Interventions

DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
OTHER: Placebo
OTHER: Quality-of-Life Assessment
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

National Cancer Institute (NCI)